Author

Jewel Johanns 1

1 Janssen Research &am

CLINICAL OUTCOMES IN CONTINUOUS CLINICAL RESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUB-ANALYSES FROM THE PURSUIT-SC MAINTENANCE STUDY

W Reinisch, Brian G. Feagan, C Marano, R Strauss, Jewel Johanns, H Zhang, H Weng, R Yao, Dino Tarabar, Zbigniew Hebzda

DIFFERENT INDUCTION RESPONSE CRITERIA DO NOT INFLUENCE 1 YEAR RESPONSE AND REMISSION RATES OF USTEKINUMAB 90 MG Q8W IN PHASE III PROGRAM

Dominik Naessens, Jewel Johanns, Christopher Gasink

EARLY AND SUSTAINED REMISSION AFTER TREATMENT WITH SC ADMINISTERED GOLIMUMAB IS ASSOCIATED WITH NORMALIZED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: POSTHOC-ANALYSIS FROM PURSUIT INDUCTION AND MAIN

Walter Reinisch, Brian G. Feagan, Colleen W. Marano, Richard S Strauss, C. Han, T Gathany, Jewel Johanns, Hongjie Zhang, Peter R. Gibson, John Collins, Paul Rutgeerts, Jean-Frederic Colombel, Brian G. Feagan, Gunnar Jarnerot, William Sandborn

Early Improvement After Intravenous Ustekinumab Induction in Patients with Ulcerative Colitis: Results from the UNIFI Induction Trial

Bruce E. Sands, Maria T. Abreu, C Marano, Thomas Baker, Christopher D. O'Brien, Hongyan Zhang, Jewel Johanns, David Rowbotham, Rupert W Leong, Silvio Danese

EARLY PRO-2 SYMPTOM REMISSION FOLLOWING GUSELKUMAB INDUCTION TREATMENT: RESULTS THROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY

William J. Sandborn, Tadakazu Hisamatsu, Kathleen Weisel, Susana Gonzalez, Mary Ellen Frustaci, Zijiang Yang, Jewel Johanns, Matthew Germinaro, Brian Feagan, Aniita Afzali, Walter Reinisch, Jane Andrews, Omoniyi J. Adedokun, Chenglong Han

EARLY RESPONSES IN PATIENT-REPORTED OUTCOMES ARE PREDICTORS FOR MUCOSAL HEALING IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH GOLIMUMAB- RESULTS FROM PURSUIT SC INDUCTION

Walter Reinisch, Brian G. Feagan, Colleen W. Marano, Richard S Strauss, C. Han, Jewel Johanns, Hongjie Zhang, Peter R. Gibson, John Collins, Paul Rutgeerts, William Sandborn, Jean-Frederic Colombel, Brian G. Feagan, Gunnar Jarnerot

EFFICACY AND SAFETY OF DOSE ADJUSTMENT AND DELAYED RESPONSE TO USTEKINUMAB IN MODERATE ?SEVERE CROHN?S DISEASE PATIENTS: RESULTS FROM THE IM-UNITI MAINTENANCE STUDY

Bruce E. Sands, Christopher Gasink, Douglas Jacobstein, Long Long Gao, Jewel Johanns, Philippe Szapary, Jean-Frederic Colombel, Stephan Targan, Subrata Ghosh, William Sandborn

EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN'S DISEASE: RESULTS FROM IM-UNITI LONG-TERM EXTENSION THROUGH 3 YEARS

William Sandborn, Paul Rutgeerts, Douglas Jacobstein, Christopher Gasink, Rishit Patel, Bin Zou, Jewel Johanns, Bruce E. Sands, Stephen B Hanauer, Stephan Targan, Subrata Ghosh, Willem de Villiers, Jean-Frederic Colombel, Brian G. Feagan

Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 2 Years: UNIFI Long-term Extension

Bruce E. Sands, William Sandborn, Remo Panaccione, Christopher D. O'Brien, Hongyan Zhang, Jewel Johanns, Yiying Zhou, Ilia Tikhonov, Laurent Peyrin-Biroulet, Gert Van Assche, Silvio Danese, Stephan Targan, Maria T. Abreu, Tadakazu Hisamatsu, Ellen Scherl, Rupert W Leong, David Rowbotham, Ramesh P. Arasaradnam, Colleen W.

EFFICACY OF USTEKINUMAB FOR INDUCTION AND MAINTENANCE OF ENDOSCOPIC HEALING IN PATIENTS WITH CROHN?S DISEASE

Paul Rutgeerts, Christopher Gasink, Daphne Chan, Yinghua Lang, Paul Pollack, Stephen B Hanauer, Douglas C. Wolf, Douglas Jacobstein, Jewel Johanns, Philippe Szapary, Brian G. Feagan, William Sandborn

Item 1 - 10 / 24
1
2 3